NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Niagen Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$2.50+0.01 (+0.40%)
Close on Oct 19, 2026
- Market cap
- $206.26M
- P/E (TTM)
- 13.9
- Dividend yield
- –
Niagen Bioscience, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Products segment | $97.67M | $76.77M | $69.53M | $60.11M | $56.71M | $47.09M | $36.08M | $18.45M | $5.46M | $0 | 75.5% | +27.2% |
| Ingredients segment | $28.68M | $19.81M | $11.14M | $8.74M | $7.41M | $9.20M | $6.20M | $8.57M | $11.15M | $16.77M | 22.2% | +44.7% |
| Analytical Reference Standards and Services segment | $3.08M | $3.01M | $2.91M | $3.20M | $3.34M | $2.97M | $4.02M | $4.54M | – | – | 2.4% | +2.2% |
| Pharmaceuticals segment | $0 | $0 | – | – | – | – | – | – | – | – | 0.0% | – |
| Scientific and Regulatory Consulting segment [Member] | – | – | – | – | – | – | – | – | – | $665.44K | – | – |
| Analytical Reference Standards Services [Member] | – | – | – | – | – | – | – | – | $4.58M | $4.89M | – | – |
| Corporate and Other Segment [Member] | – | – | – | – | – | $0 | $0 | $0 | $0 | $0 | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Products segment | $28.43M | $17.18M | $14.49M | $6.51M | $5.59M | $6.25M | $483.00K | -$7.69M | -$502.00K | $0 | +65.5% |
| Ingredients segment | $16.75M | $10.90M | $5.42M | $3.61M | $3.72M | $5.12M | $2.25M | $1.38M | $732.00K | $5.17M | +53.7% |
| Analytical Reference Standards and Services segment | $396.00K | -$215.00K | -$522.00K | -$459.00K | -$10.00K | -$464.00K | $400.00K | $345.00K | – | – | -284.2% |
| Pharmaceuticals segment | -$2.23M | -$1.76M | – | – | – | – | – | – | – | – | +27.0% |
| Scientific and Regulatory Consulting segment [Member] | – | – | – | – | – | – | – | – | – | $189.01K | – |
| Analytical Reference Standards Services [Member] | – | – | – | – | – | – | – | $345.00K | $1.04M | $1.14M | – |
| Corporate and Other Segment [Member] | – | – | – | – | – | -$30.45M | -$34.43M | -$27.21M | -$17.64M | -$9.21M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Niagen Bioscience's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.